The functional role of P2 purinergic receptors in the progression of gastric cancer.

IF 3 4区医学 Q2 NEUROSCIENCES Purinergic Signalling Pub Date : 2024-03-12 DOI:10.1007/s11302-024-10000-7

Fei-Long Zou, Ji-Peng Liu, Cheng Zuo, Peng-Fei He, Jin-Xiong Ye, Wen-Jun Zhang

{"title":"The functional role of P2 purinergic receptors in the progression of gastric cancer.","authors":"Fei-Long Zou, Ji-Peng Liu, Cheng Zuo, Peng-Fei He, Jin-Xiong Ye, Wen-Jun Zhang","doi":"10.1007/s11302-024-10000-7","DOIUrl":null,"url":null,"abstract":"<p><p>Studies have confirmed that P2 purinergic receptors (P2X receptors and P2Y receptors) expressed in gastric cancer (GC) cells and GC tissues and correlates with their function. Endogenous nucleotides including ATP, ADP, UTP, and UDP, as P2 purinergic receptors activators, participate in P2 purinergic signal transduction pathway. These activated P2 purinergic receptors regulate the progression of GC mainly by mediating ion channels and intracellular signal cascades. It is worth noting that there is a difference in the expression of P2 purinergic receptors in GC, which may play different roles in the progression of GC as a tumor promoting factor or a tumor suppressor factor. Among them, P2 × 7, P2Y2 and P2Y6 receptors have certain clinical significance in patients with GC and may be used as biological molecular markers for the prediction of patients with GC. Therefore, in this paper, we discuss the functional role of nucleotide / P2 purinergic receptors signal axis in regulating the progression of GC and that these P2 purinergic receptors may be used as potential molecular targets for the prevention and treatment of GC.</p>","PeriodicalId":20952,"journal":{"name":"Purinergic Signalling","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Purinergic Signalling","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11302-024-10000-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Studies have confirmed that P2 purinergic receptors (P2X receptors and P2Y receptors) expressed in gastric cancer (GC) cells and GC tissues and correlates with their function. Endogenous nucleotides including ATP, ADP, UTP, and UDP, as P2 purinergic receptors activators, participate in P2 purinergic signal transduction pathway. These activated P2 purinergic receptors regulate the progression of GC mainly by mediating ion channels and intracellular signal cascades. It is worth noting that there is a difference in the expression of P2 purinergic receptors in GC, which may play different roles in the progression of GC as a tumor promoting factor or a tumor suppressor factor. Among them, P2 × 7, P2Y2 and P2Y6 receptors have certain clinical significance in patients with GC and may be used as biological molecular markers for the prediction of patients with GC. Therefore, in this paper, we discuss the functional role of nucleotide / P2 purinergic receptors signal axis in regulating the progression of GC and that these P2 purinergic receptors may be used as potential molecular targets for the prevention and treatment of GC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

P2嘌呤能受体在胃癌进展中的功能作用

研究证实，P2嘌呤能受体（P2X受体和P2Y受体）在胃癌细胞和胃癌组织中表达，并与其功能相关。内源性核苷酸（包括 ATP、ADP、UTP 和 UDP）作为 P2 嘌呤能受体激活剂，参与 P2 嘌呤能信号转导通路。这些被激活的 P2 嘌呤能受体主要通过介导离子通道和细胞内信号级联来调节 GC 的进展。值得注意的是，P2嘌呤能受体在GC中的表达存在差异，它们可能作为肿瘤促进因子或肿瘤抑制因子在GC的进展过程中发挥不同的作用。其中，P2 ×7、P2Y2 和 P2Y6 受体在 GC 患者中具有一定的临床意义，可作为预测 GC 患者的生物学分子标记。因此，本文探讨了核苷酸/P2嘌呤能受体信号轴在调控GC进展中的功能作用，以及这些P2嘌呤能受体可作为预防和治疗GC的潜在分子靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Purinergic Signalling 医学-神经科学

CiteScore

6.60

自引率

17.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells.